Last €4.55 EUR
Change Today -0.002 / -0.04%
Volume 0.0
AM6 On Other Exchanges
As of 3:24 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (AM6) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - €5.90
52 Week Low
04/17/14 - €1.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMICUS THERAPEUTICS INC (AM6)

amicus therapeutics inc (AM6) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (AM6) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (AM6) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Chief Operating Officer
Total Annual Compensation: $475.0K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $247.4K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (AM6) Key Developments

Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

Amicus Therapeutics announced positive 18-month data from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations. Summary of Study 012 18-Month Results: Migalastat had a comparable effect to ERT on patients' kidney function as measured by the change in eGFR and mGFR. Levels of plasma lyso-Gb3, an important biomarker of disease, remained low and stable in patients with amenable mutations who switched from ERT to migalastat. Migalastat was generally safe and well-tolerated. Of 48 patients with GLP HEK-amenable mutations who completed Study 012, 46 (96%) elected to continue with the 12-month treatment extension and 45 remain on migalastat as their only treatment for Fabry disease.

Amicus Therapeutics, Inc. - Special Call

To discuss positive 18-month data from its second phase 3 study (study 012) of the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations

Amicus Therapeutics, Inc. Announces Executive Changes

Amicus Therapeutics, Inc. announced that Chairman and CEO John F. Crowley, a commissioned officer in the United States Navy Reserve, has been ordered to temporary active duty in support of Operation Enduring Freedom (Afghanistan) for a period of approximately 32 weeks beginning by the end of September 2014. Mr. Crowley will remain as Chairman and CEO and a member of the Amicus Board of Directors and expects to continue to advise the company on major strategic and business issues during this leave of absence. Bradley Campbell, Chief Operating Officer, will oversee the company's day to day operations and will chair the company's executive leadership team in Mr. Crowley's absence. Mr. Crowley is expected to return from active duty service and to resume his full responsibilities as Amicus Chairman and CEO in the second quarter of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AM6:GR €4.55 EUR -0.002

AM6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AM6.
View Industry Companies

Industry Analysis


Industry Average

Valuation AM6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 316.3x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 299.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at